Almirall Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 5/6
Almirall verzeichnete einen durchschnittlichen jährlichen Gewinnzuwachs von 22.8%, während die Gewinne der Branche Pharmaceuticals jährlich um gewachsen und zwar um 4.9%. Die Umsätze verzeichneten einen durchschnittlichen jährlichen Gewinnzuwachs von gewachsen von 6.8%. Die Eigenkapitalrendite von Almirall beträgt 2.6% und die Nettomargen betragen 3.6%.
Wichtige Informationen
22.81%
Wachstumsrate der Gewinne
13.93%
EPS-Wachstumsrate
| Pharmaceuticals Wachstum der Industrie | 4.99% |
| Wachstumsrate der Einnahmen | 6.79% |
| Eigenkapitalrendite | 2.64% |
| Netto-Marge | 3.56% |
| Nächste Ertragsaktualisierung | 24 Jul 2026 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
ALM: Future Re-Rating Will Depend On Dermatology Execution And Pipeline Delivery
Analysts have nudged their price target on Almirall higher to €13.91 from €13.69, reflecting updated assumptions on revenue growth, profit margins and future P/E, despite a recent downgrade in stance from BNP Paribas. Analyst Commentary Analysts are sending mixed signals on Almirall, with a higher price target sitting alongside a more cautious rating.ALM: Future Re-Rating Will Rely On Dermatology Pipeline And Execution
Analysts slightly trimmed their price target for Almirall to €13.69 from €13.86, citing updated assumptions around revenue growth, profit margins, and future P/E expectations. What's in the News Almirall plans to start a phase III study in the first half of 2026 evaluating Lebrikizumab (Ebglyss) for nummular eczema.ALM: Future Re-Rating Will Depend On Pipeline Execution And Ebglyss Ramp-Up
Narrative update on Almirall Analysts have raised their price target on Almirall to €14.50, citing what they see as a still-compelling valuation, along with expectations for Ebglyss ramp-up, upcoming clinical readouts, and potential in-licensing and M&A to support the mid-stage pipeline. Analyst Commentary Recent research points to a target price of €14.50 for Almirall, with the view that the shares still offer a compelling entry point despite a prior rebound in the stock.ALM: Future Re-Rating Will Hinge On Ebglyss Uptake And Pipeline Delivery
Analysts have modestly raised their price target on Almirall to EUR 14.50, citing expectations for a continued valuation re-rating supported by the ramp up of Ebglyss, upcoming clinical readouts, and potential in-licensing and M&A to bolster the mid-stage pipeline. Analyst Commentary Analyst views on Almirall remain broadly positive, with recent coverage highlighting both upside drivers and execution risks as the company advances its dermatology portfolio.Market Cool On Almirall, S.A.'s (BME:ALM) Revenues
There wouldn't be many who think Almirall, S.A.'s ( BME:ALM ) price-to-sales (or "P/S") ratio of 2.6x is worth a...ALM: Future Re-Rating Will Depend On Dermatology Execution And Pipeline Delivery
Analysts have modestly raised their 12 month price target for Almirall to EUR 14.50, citing expectations that a continued re rating driven by Ebglyss ramp up, upcoming clinical readouts, and potential in licensing and M&A could support upside from current levels. Analyst Commentary Analysts note that Almirall's investment case is increasingly driven by visible growth levers in medical dermatology, but also caution that execution on product ramps and pipeline milestones will be critical to sustaining the recent share price rebound.ALM: Pipeline Milestones And Product Launch Momentum Will Drive Re-Rating
Analysts have increased their price target for Almirall from €13.30 to €13.87. They cite a compelling valuation, strong pipeline prospects, and expectations for continued growth driven by product launches and strategic developments.Almirall's (BME:ALM) Strong Earnings Are Of Good Quality
When companies post strong earnings, the stock generally performs well, just like Almirall, S.A.'s ( BME:ALM ) stock...Almirall, S.A. (BME:ALM) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
It's been a good week for Almirall, S.A. ( BME:ALM ) shareholders, because the company has just released its latest...We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...The Almirall, S.A. (BME:ALM) Interim Results Are Out And Analysts Have Published New Forecasts
Almirall, S.A. ( BME:ALM ) came out with its interim results last week, and we wanted to see how the business is...European Demographics Will Drive Advancements In Dermatology Treatments
Strong specialty product launches and robust R&D pipeline are expected to drive growth, improve margins, and boost Almirall's market position in innovative dermatology.Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 44% Above Its Share Price
Key Insights The projected fair value for Almirall is €14.08 based on 2 Stage Free Cash Flow to Equity Current share...Why We're Not Concerned About Almirall, S.A.'s (BME:ALM) Share Price
With a median price-to-sales (or "P/S") ratio of close to 2.2x in the Pharmaceuticals industry in Spain, you could be...Statutory Profit Doesn't Reflect How Good Almirall's (BME:ALM) Earnings Are
Almirall, S.A. ( BME:ALM ) recently posted some strong earnings, and the market responded positively. Our analysis...These 4 Measures Indicate That Almirall (BME:ALM) Is Using Debt Extensively
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Almirall, S.A.'s (BME:ALM) Popularity With Investors Is Clear
There wouldn't be many who think Almirall, S.A.'s ( BME:ALM ) price-to-sales (or "P/S") ratio of 1.9x is worth a...Almirall, S.A. (BME:ALM) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year
Almirall, S.A. ( BME:ALM ) shareholders are probably feeling a little disappointed, since its shares fell 2.9% to €8.52...Almirall (BME:ALM) Has A Somewhat Strained Balance Sheet
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Investors Continue Waiting On Sidelines For Almirall, S.A. (BME:ALM)
You may think that with a price-to-sales (or "P/S") ratio of 2x Almirall, S.A. ( BME:ALM ) is a stock worth checking...Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 90% Above Its Share Price
Key Insights Using the 2 Stage Free Cash Flow to Equity, Almirall fair value estimate is €18.31 Current share price of...Market Participants Recognise Almirall, S.A.'s (BME:ALM) Revenues
There wouldn't be many who think Almirall, S.A.'s ( BME:ALM ) price-to-sales (or "P/S") ratio of 1.9x is worth a...These 4 Measures Indicate That Almirall (BME:ALM) Is Using Debt Reasonably Well
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Here's Why Almirall (BME:ALM) Can Manage Its Debt Responsibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Is There An Opportunity With Almirall, S.A.'s (BME:ALM) 21% Undervaluation?
Key Insights Almirall's estimated fair value is €11.86 based on 2 Stage Free Cash Flow to Equity Almirall's €9.37 share...We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Is There An Opportunity With Almirall, S.A.'s (BME:ALM) 31% Undervaluation?
Key Insights Almirall's estimated fair value is €11.37 based on 2 Stage Free Cash Flow to Equity Current share price of...Aufschlüsselung der Einnahmen und Ausgaben
Wie Almirall Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Gewinn | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 31 Mar 26 | 1,121 | 40 | 263 | -1 |
| 31 Dec 25 | 1,115 | 46 | 264 | 0 |
| 30 Sep 25 | 1,085 | 42 | 256 | 12 |
| 30 Jun 25 | 1,054 | 21 | 249 | 0 |
| 31 Mar 25 | 1,028 | 24 | 246 | 9 |
| 31 Dec 24 | 991 | 10 | 235 | 0 |
| 30 Sep 24 | 953 | -45 | 237 | 12 |
| 30 Jun 24 | 932 | -35 | 220 | 0 |
| 31 Mar 24 | 915 | -39 | 214 | 3 |
| 31 Dec 23 | 899 | -38 | 209 | 0 |
| 30 Sep 23 | 907 | 7 | 209 | 7 |
| 30 Jun 23 | 898 | -11 | 201 | 0 |
| 31 Mar 23 | 882 | -8 | 205 | 3 |
| 31 Dec 22 | 879 | 4 | 202 | 0 |
| 30 Sep 22 | 864 | 9 | 207 | 24 |
| 30 Jun 22 | 856 | 29 | 197 | 0 |
| 31 Mar 22 | 843 | -50 | 190 | 8 |
| 31 Dec 21 | 837 | -41 | 188 | 0 |
| 30 Sep 21 | 814 | -22 | 201 | -10 |
| 30 Jun 21 | 809 | -11 | 185 | 0 |
| 31 Mar 21 | 790 | 55 | 188 | -8 |
| 31 Dec 20 | 814 | 74 | 177 | 0 |
| 30 Sep 20 | 849 | 63 | 167 | -8 |
| 30 Jun 20 | 872 | 86 | 188 | 0 |
| 31 Mar 20 | 926 | 121 | 188 | 0 |
| 31 Dec 19 | 911 | 106 | 189 | 0 |
| 30 Sep 19 | 858 | 85 | 227 | 9 |
| 30 Jun 19 | 884 | 88 | 182 | 0 |
| 31 Mar 19 | 789 | 80 | 209 | 3 |
| 31 Dec 18 | 811 | 78 | 183 | 0 |
| 30 Sep 18 | 714 | -111 | 176 | -10 |
| 30 Jun 18 | 730 | -179 | 196 | 0 |
| 31 Mar 18 | 687 | -293 | 195 | -6 |
| 31 Dec 17 | 677 | -304 | 207 | 0 |
| 30 Sep 17 | 735 | -128 | 215 | 5 |
| 30 Jun 17 | 755 | -78 | 214 | 0 |
| 31 Mar 17 | 821 | 73 | 216 | 5 |
| 31 Dec 16 | 822 | 75 | 213 | 0 |
| 30 Sep 16 | 778 | 162 | 230 | 10 |
| 30 Jun 16 | 743 | 154 | 210 | 0 |
| 31 Mar 16 | 721 | 111 | 204 | 2 |
| 31 Dec 15 | 738 | 132 | 201 | 0 |
| 30 Sep 15 | 783 | 479 | 190 | -28 |
| 30 Jun 15 | 802 | 488 | 244 | 0 |
Qualität der Erträge: ALM hat hohe Qualitätseinkünfte.
Wachsende Gewinnspanne: ALMDie aktuellen Gewinnspannen (3.6%) sind höher als im letzten Jahr (2.4%).
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: ALMIn den letzten 5 Jahren sind die Einnahmen von 22.8% pro Jahr erheblich gestiegen.
Beschleunigtes Wachstum: ALMDas Gewinnwachstum des Unternehmens im letzten Jahr (63.7%) übertrifft seinen 5-Jahres-Durchschnitt (22.8% pro Jahr).
Erträge im Vergleich zur Industrie: ALM Das Gewinnwachstum im vergangenen Jahr (63.7%) übertraf das der Branche Pharmaceuticals 16.1% .
Eigenkapitalrendite
Hohe Eigenkapitalrendite: ALMDie Eigenkapitalrendite des Unternehmens (2.6%) wird als niedrig angesehen.
Kapitalrendite
Rendite auf das eingesetzte Kapital
Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/21 05:50 |
| Aktienkurs zum Tagesende | 2026/05/21 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Almirall, S.A. wird von 27 Analysten beobachtet. 11 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| null null | Banco de Sabadell. S.A. |
| Luis Arredondo | Banco de Sabadell. S.A. |
| Jaime Escribano | Banco Santander |